FY2024 EPS Estimates for PDS Biotechnology Co. (NASDAQ:PDSB) Increased by Cantor Fitzgerald

PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for shares of PDS Biotechnology in a research report issued on Thursday, May 16th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings of ($1.29) per share for the year, up from their prior forecast of ($1.64). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for PDS Biotechnology's current full-year earnings is ($1.41) per share.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last issued its earnings results on Wednesday, May 15th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.07.

Other equities research analysts have also issued research reports about the stock. StockNews.com lowered shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research note on Saturday, March 16th. B. Riley reiterated a "buy" rating and issued a $11.00 price objective (down from $14.00) on shares of PDS Biotechnology in a report on Thursday, March 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $21.00 price objective on shares of PDS Biotechnology in a report on Wednesday, May 15th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, PDS Biotechnology currently has a consensus rating of "Moderate Buy" and an average price target of $17.33.

PDS Biotechnology Stock Down 3.2 %

Shares of PDS Biotechnology stock traded down $0.11 during trading on Monday, reaching $3.38. The company had a trading volume of 476,228 shares, compared to its average volume of 840,681. The company has a market cap of $123.98 million, a price-to-earnings ratio of -2.43 and a beta of 1.75. The firm's fifty day moving average is $3.74 and its 200-day moving average is $4.76. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.56 and a current ratio of 4.56. PDS Biotechnology has a fifty-two week low of $2.59 and a fifty-two week high of $10.27.

Institutional Investors Weigh In On PDS Biotechnology

Several hedge funds have recently made changes to their positions in the company. EP Wealth Advisors LLC purchased a new stake in PDS Biotechnology in the 3rd quarter worth approximately $52,000. SG Americas Securities LLC acquired a new stake in PDS Biotechnology in the 4th quarter worth $52,000. Raymond James Financial Services Advisors Inc. acquired a new stake in PDS Biotechnology in the 3rd quarter worth $56,000. Inspirion Wealth Advisors LLC lifted its holdings in shares of PDS Biotechnology by 1.7% during the 4th quarter. Inspirion Wealth Advisors LLC now owns 336,594 shares of the company's stock worth $1,733,000 after acquiring an additional 5,720 shares during the period. Finally, Corton Capital Inc. bought a new position in shares of PDS Biotechnology during the 3rd quarter worth about $112,000. Hedge funds and other institutional investors own 26.84% of the company's stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.